COMMUNIQUÉS West-GlobeNewswire
-
Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 22nd Annual Meeting of the Society of Neuro-Oncology (SNO)
16/11/2017 - 13:00 -
Arcturus Therapeutics Announces Completion of Merger with Alcobra Ltd. and Commences Trading on the Nasdaq Global Market
16/11/2017 - 13:00 -
MediWound Reports Third Quarter 2017 Financial Results
16/11/2017 - 13:00 -
LHC Group and Almost Family Announce Merger of Equals to Create Leading National Provider of In-Home Healthcare Services
16/11/2017 - 12:45 -
Purepoint Uranium Group Inc: Hook Lake JV Partners Approve $4 Million For 2018 Exploration Budget
16/11/2017 - 12:45 -
Merit Medical Signs Purchase Agreement with BD for Divestment Assets
16/11/2017 - 12:30 -
BioCryst to Present at 29th Annual Piper Jaffray Healthcare Conference
16/11/2017 - 12:00 -
Orphazyme A/S: Major shareholder announcement
16/11/2017 - 11:06 -
Orphazyme A/S: Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Orphazymes' shares
16/11/2017 - 10:31 -
Orphazyme A/S: New share-based incentive programme
16/11/2017 - 09:31 -
Orphazyme A/S: Stabilisation period begins
16/11/2017 - 09:16 -
What You Need to Know About Winter Allergies
16/11/2017 - 09:00 -
Summit Therapeutics plc : Miscellaneous
16/11/2017 - 08:01 -
ABLYNX ANNOUNCES RESULTS FOR THE FIRST NINE MONTHS OF 2017 AND A YEAR-TO-DATE BUSINESS UPDATE
16/11/2017 - 07:02 -
TiGenix announces approval of trade name for lead development candidate Cx601 in Europe
16/11/2017 - 07:01 -
TiGenix annonce l'approbation d'un nom commercial en Europe pour son produit candidat en phase de développement, le Cx601
16/11/2017 - 07:01 -
Orphazyme announces the result of its IPO, including an offer price of DKK 80 per share
16/11/2017 - 06:31 -
Orphazyme A/S: Election of new members of the Board of Directors
16/11/2017 - 06:16 -
Arsanis Announces Pricing of Initial Public Offering
16/11/2017 - 05:20
Pages